Inh Agepha

Isoniazid, the active ingredient in Inh Agepha, is an antitubercular agent presented as an oral dosage form (strength not specified) for oral use. It treats active and latent tuberculosis in adults and children as part of standard therapy.

GNH USA supplies Inh Agepha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoniazid is an antitubercular drug used in the management of Mycobacterium tuberculosis infections.

Active tuberculosis: forms part of combination therapy to eradicate the bacteria and achieve cure. Latent tuberculosis infection: used alone or with rifampicin to prevent progression to active disease. TB prophylaxis in high‑risk contacts: administered to individuals with recent exposure to reduce the chance of developing active TB.

Isoniazid may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Vomiting - Loss of appetite - Peripheral neuropathy (mild) - Skin rash - Fever

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe peripheral neuropathy - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Drug‑induced lupus erythematosus - Hemolytic anemia - Seizures (especially in high doses or renal impairment)

When prescribing isoniazid, clinicians should consider several safety measures.

Liver function monitoring: obtain baseline hepatic enzymes and repeat periodically. Vitamin B6 supplementation: co‑administer pyridoxine to reduce neuropathy risk. Hypersensitivity avoidance: discontinue if severe allergic reaction occurs. Pre‑existing neuropathy caution: monitor for worsening symptoms. Pregnancy and lactation assessment: evaluate risk‑benefit before use. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Isoniazid interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Rifampicin: induces hepatic enzymes, reducing isoniazid levels. - Carbamazepine: increases hepatotoxic risk. - Phenytoin: may exacerbate liver injury. - Alcohol: additive hepatotoxic effect.

Moderate Interactions (Monitor Closely): - Acetaminophen: combined use may increase liver enzyme elevations. - NSAIDs: monitor for additive gastrointestinal irritation. - Warfarin: isoniazid can potentiate anticoagulant effect, requiring INR checks. - Antiretrovirals (e.g., zidovudine): may enhance hematologic toxicity.